萨罗格利塔萨尔在改善短暂弹性图表参数中的作用 显著和高级代谢功能障碍相关的稳形肝炎
1Gastroenterology, Kak Liver and Gut Center, Nehru Nagar, Ghaziabad, IND.
Cureus
|January 13, 2026
概括
在患有代谢功能障碍相关的脂肪肝炎 (MASH) 的患者中,萨罗格利塔萨尔显著改善了肝硬度,脂肪和脂质概况. 这种双重PPAR-α/γ激动剂在52周的时间内在早期和晚期纤维化阶段都表现出有效性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是肝脏和心脏代谢疾病的主要原因.
- 萨罗格利塔扎尔是一种PPAR-α/γ激动剂,它解决了MASH的肝脏和代谢方面的问题.
- 在临床实践中,关于萨罗格利塔萨尔在MASH中的疗效的现实数据对临床实践至关重要.
研究的目的:
- 为了评估萨罗格利塔萨尔在MASH患者中的实际有效性.
- 评估肝硬度,肥胖症,肝酶和脂质配置文件的改善情况.
- 为了确定saroglitazar在不同纤维化阶段的影响.
主要方法:
- 一个回顾性,单中心的观察性研究,对204名MASH患者进行了52周的每日4毫克萨罗格利塔萨尔治疗.
- 根据基线肝硬度,患者被分为显著纤维化 (<14 kPa) 和高级纤维化 (≥14 kPa) 组.
- 关键参数包括肝硬 (LSM),脂肪酸 (CAP),ALT,AST,总胆固醇和LDL-C在基线,24周和52周被分析.
主要成果:
- 在两组纤维化患者中都观察到肝硬度 (LSM) 和脂肪脂肪症 (CAP) 的显著降低.
- 在这两组中,ALT和AST水平大幅下降,表明肝炎的减少.
- 总胆固醇和LDL-C的改善,以及良好的安全性,没有严重的不良事件.
结论:
- 沙罗格利塔萨尔每天4毫克有效地改善了真实世界MASH队列中的肝硬度,脂肪酸,氨酸酶和脂质参数.
- 该药物在MASH的早期和晚期都显示出显著的肝代谢益处.
- 这些发现支持saroglitazar在管理不同程度肝纤维化MASH患者中的作用.
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
538
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
538
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593


